News | April 09, 2009

NMT Medical’s STARFlex PMA Approved as Ventricular Septal Defect Repair Implant


April 9, 2009 - NMT Medical Inc. has received Pre-Market Approval (PMA) from the FDA to being commercial sales of the STARFlex cardiac septal repair implant for patients with ventricular septal defects (VSD).

STARFlex is constructed from a low profile, MP35N framework to which a knitted Dacron fabric is securely attached. The implant can be placed in the heart to close the VSD using a catheter during a minimally invasive procedure in the cath lab, providing an alternative to open-heart surgery.

Using spring coils in the framework, the STARFlex implant can be collapsed into a catheter for insertion into the heart. Once inserted through the catheter, the STARFlex implant is opened, with one umbrella positioned on each side of the defect. The design of the frame reportedly allows the device to conform to variations in the anatomy of the septum, keeping a low profile without obstructing the flow of blood through the atria.

For information: www.nmtmedical.com.


Related Content

News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
Subscribe Now